X

Drug Profile

GB 104

Alternative Names: GB-104; GB-X01

Latest Information Update: 31 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GI Biome
Class Antineoplastics; Bacteria
Mechanism of Action Bacteria replacements; Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Colorectal cancer

Most Recent Events

31 Jul 2024 GI Biome has patents pending for GB 104 (GI Biome pipeline, July 2024)
28 Apr 2023 Phase-I clinical trials in Colorectal cancer in South Korea (PO) (NCT05943041)
06 Feb 2023 The Ministry of Food and Drug Safety approves an IND application for GB 104 in Colorectal cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com